Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HECTOR: Octreotide in Advanced HCC
NCT00386984Phase 3Completed
- Sponsor
- University Hospital Freiburg
- Start
- Oct 1999
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Octreotide with Placebo (2 arms). Primary endpoint: Overall Survival Time. Started Oct 1999; status: completed.
02
Drugs
octreotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00386984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00386984.